Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.9 USD | +15.70% | +31.91% | +39.01% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.53M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-12.3
x | P/E ratio 2025 * |
-11.5
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | +3.34% | ||
1 week | +15.66% | ||
Current month | -34.87% | ||
1 month | -14.23% | ||
3 months | +160.51% | ||
6 months | -47.50% | ||
Current year | +22.53% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 12.65 | +13.45% | 37 365 |
24-05-23 | 11.15 | +3.34% | 26,555 |
24-05-22 | 10.79 | -1.19% | 11,880 |
24-05-21 | 10.92 | -1.62% | 15,370 |
24-05-20 | 11.1 | +15.75% | 59,525 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.53% | 11.53M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.94% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- AVTX Stock